在本妥昔单抗时代，复发难治性经典型霍奇金淋巴瘤患者在移植前需要多种挽救方案，仍有显著缓解情况。
Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.
作者信息
Abuelgasim Khadega A, Ghazi Samer, Alahmari Bader, Alhejazi Ayman, Alaskar Ahmed, Alzahrani Mohsen, Damlaj Moussab
机构信息
Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
出版信息
Leuk Res Rep. 2021 Oct 21;16:100276. doi: 10.1016/j.lrr.2021.100276. eCollection 2021.
Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥two lines. At 2 years, the estimated PFS and OS for patients requiring one vs. ≥two lines was 71.2% (50.1-84.7) vs. 51.9% (27.6-71.6), = 0.16 and 84.6% (63-94) vs. 84% (58-95), = 0.88, respectively. Patients requiring ≥two salvage lines prior to HCT can achieve comparable outcomes to those requiring one, possibly due to brentuximab vedotin leading to higher CMR rates.
一线挽救治疗难治的复发/难治性经典型霍奇金淋巴瘤（R/R cHL）患者预后较差。在此，我们报告在化疗免疫治疗时代，需要≥二线与一线治疗的R/R cHL患者的预后情况。在55例R/R cHL患者中，33例（60%）需要一线治疗，22例（40%）需要≥二线治疗。2年时，需要一线与≥二线治疗患者的估计无进展生存期（PFS）和总生存期（OS）分别为71.2%（50.1 - 84.7）对51.9%（27.6 - 71.6），P = 0.16；以及84.6%（63 - 94）对84%（58 - 95），P = 0.88。在造血干细胞移植（HCT）前需要≥二线挽救治疗的患者可取得与需要一线治疗患者相当的预后，这可能是由于维布妥昔单抗导致更高的完全缓解率。
Zotero 插件